Home Page Link AgBioWorld Home Page
About AgBioWorld Donations Ag-Biotech News Declaration Supporting Agricultural Biotechnology Ag-biotech Info Experts on Agricultural Biotechnology Contact Links Subscribe to AgBioView Home Page

AgBioView Archives

A daily collection of news and commentaries on

Subscribe AgBioView Subscribe

Search AgBioWorld Search

AgBioView Archives





September 20, 2000


GM Soy, Starlink question, Biosafety Data


Barnes, R. L. (2000). Why the American Soybean Association supports
transgenic soybeans. Pest Manag Sci 56:580-583.

"By planting soybeans tolerant to glyphosate, farmers are able to
implement low- or no-till farming, a practice that minimises soil erosion
and run-off. It was estimated that ca 37 million tons of topsoil will have
been preserved by 2020."

"Reduced working of the soil saves 33 litres of fuel per hectare,
translating into a reduction of 400 000 tons of carbon entering the
atmosphere as carbon dioxide over the period to 2020."

"Leaving crop residues undisturbed also provides shelter for wildlife that
is not available when normal ploughing practices are undertaken. Farmers
already point towards increased bird and small animal sightings when they
leave the soil undisturbed."

Wayne Parrott
Dept. Crop & Soil Sciences
University of Georgia
Athens, GA 30602-7272(706)
542-0928/fax 0914

Subj: StarLink Corn - Question
Date: Wed, 20 Sep 2000 6:52:43 PM Eastern Daylight Time
From: Roger Morton

I have a question. If, as this article from AP says, the Starlink corn is
only one percent of US corn acreage and is mainly used for stock feed how
can it be contaminating taco shells at 1% as claimed by GeneticID. This
implies that there is absolutely no segregation of Starlink Corn. Can this
be true?

>Researchers Say Consumers Shouldn't Be Too Concerned
>Associated Press
>19 September 2000

>The crop, genetically engineered to kill an insect, is grown on less
than1 percent of the total U.S. corn acreage and approved for use only
in>animal feed.

--Opinons expressed in this posting are personal and do not reflect
theposition of my employer

Date: Sep 21 2000 15:10:04 EDT
From: Giovanni Ferraiolo

BIOSAFETY-DATA Announcement of a new ICGEB service now available for the
dissemination of scientific findings in biosafety via e-mail.

A new distribution list, BIOSAFETY-DATA, has been set up on the ICGEB
server. The automated service will send to the subscribers a monthly
e-mail message with the last bibliographic references added to the ICGEB
biosafety database.

A copy of the bibliographic references mailed outby BIOSAFETY-DATA is
available at http://www.icgeb.trieste.it/biosafety/bsfdata3.htm.

Subscription to the list is free. Posting to the list isreserved to list
owner only.The ICGEB BIOSAFETY DATABASE (available
athttp://www.icgeb.trieste.it/biosafety/bsfdata1.htm ) is a bibliographic,
searchable index of scientific articles (fullreferences + abstracts) on
"Biosafety and Risk assessment for the environmental release of
genetically modified organisms (GMOs)". It collects articles published
since 1990, on international, peer reviewed, scientific journals. The
database is managed by the ICGEB Biosafety Unit and is updated monthly.
All the records of the database are extracted from CAB ABSTRACTS[tm], and
selected and classified by ICGEB scientists in accordance with the main
"Topics of concern for the environmental release of genetically modified
organisms(GMOs)" available

Subj: Engineered vaccine fights deadly infection
Date: Thu, 21 Sep 2000 8:49:12 AM Eastern Daylight Time
From: "Barry Hearn"


Engineered vaccine fights deadly infectionby
Daniel Q. Haney
The Associated Press

TORONTO - A vaccine has been shown for the first time to protect against
life-threatening staph infections, a major hazard among hospital patients,
researchers said yesterday.The genetically engineered vaccine was tested
first in kidney-dialysis patients, and it cut their risk of staph blood
poisoning in half for nearly a year."I am quite encouraged by this. It
could be a major breakthrough,'' said Dr. Steve Black of the Kaiser
Permanente Vaccine Study Center in Oakland.Black presented the results in
a last-minute addition to the program of the annual infectious-disease
meeting of the American Society for Microbiology.The vaccine, StaphVAX,
was created at the National Institutes of Health and is being developed by
Nabi, which financed the study.Staphylococcus aureus is a common and
ordinarily harmless inhabitant of thehuman nasal tract. It can live for
days outside the body on almost anysurface and spreads widely in
hospitals, where it can cause serious infections among those who are sick,
especially if they have weak immune defenses.Staph can be deadly if it
invades the bloodstream. It can lead to pneumonia, encephalitis, liver
abscesses and other problems.Staph infections are relatively common among
people who use needles frequently, such as diabetics and dialysis
patients, senior citizens in nursing homes and those hospitalized for
surgery and other conditions.Doctors conducted the first large test of
StaphVAX in dialysis patients because 1 to 3 percent of them get
bloodstream staph infections each year.Robert Naso, Nabi's research
director, said the company would seek approval soon from the Food and Drug
Administration to produce and sell the vaccine.The study enrolled 1,804
patients at 90 dialysis centers in California. Half got the vaccine, while
the rest took dummy shots.The vaccine appeared to quickly lower the risk
of staph. After 10 months, there were 11 serious infections among those
getting the vaccine, compared with 26 in the unprotected group.The vaccine
tells the body to make fresh antibodies against staph. After one year, the
patients' antibody levels dropped, and their protection against staph
began to fade.Dr. Julie Gerberding, head of hospital infections at the
U.S. Centers for Disease Control and Prevention, said staph is an
especially difficult problem for dialysis patients."If you can get this
much protection in them, it might work even better in other patients," she
said.Staph infections are of particular concern because the bacterium is
growing immune to the antibiotics commonly used to treat it. Half of all
staph that circulates in hospitals is resistant to methicillin, the
standard drug; it is developing resistance to vancomycin, the main backup
drug.Black said the new vaccine could be given to build up staph
resistance in surgery patients, who are prone to the infection. It might
also be used in nursing homes, among diabetics and in hospitalized people.
He said researchers also would explore giving booster doses to people who
must keep up resistance for a long time, such as those on dialysis.Black
said that until researchers began analyzing their results last week, there
was no clear evidence that boosting staph antibodies would have any effect
on serious infections. Virtually everybody has some staph antibodies,
since the bacteria are so common.

Copyright 2000 The Seattle Times Company